Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : AMIGOS INVITATIONAL YEEHAW PORTFOLIO -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (1024)	8/15/1999 8:06:00 PM
From: Sergio H	Read Replies (2) \| Respond to of 1316

Jim, I may have missed the boat on CTCH when I posted my concerns in evaluating the stock, but I certainly didn't miss the URL for the home page :-) Simply stated, I don't see how they're going to make a profit or establish a niche in a super-crowded market segment against industry giants. IFLO, on the other hand, is more and more appealing every time I review it. I noticed that IFLO obtained FDA approval for two drugs that they've been selling overseas. Missed that press release while I was on vacation. Don't know much about the market for these drugs, but it's certainly another positive development for IFLO. $$$$$$ from JNJ deal will be reflected in next quarter's earnings. Additionally, $1.2 million from licensing fee + sales revs from deal with d.j. Orthopedics will be included in the next two quarter's reports. Also, did you know that IFLO was included in Individual Investor's "Magic 25" portfolio in January? Sergio